144 ·Filed Jun 15, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001950047-26-006130
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine 10b5-1 plan sale by an insider for tax or diversification purposes. No material signal for the stock; monitor for any deviation from the established plan pattern.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
PHVS ▲ +19.23% at T+60d
NEUTRAL call ✓ call won +19.23% · α vs SPY +18.23% · entry $31.46 → $37.51
Entry anchored
Jun 15, 03:59 PM ET
via exchange tick
T+1d
+6.20%
call +6.20% · α +7.45%
$33.41
settled 4mo ago
T+5d
+5.50%
call +5.50% · α +7.73%
$33.19
settled 3mo ago
T+20d
+9.41%
call +9.41% · α +9.21%
$34.42
settled 3mo ago
T+60d
+19.23%
call +19.23% · α +18.23%
$37.51
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Director and Officer Berndt Modig filed a Form 144 to sell 2,291 shares of Pharvaris N.V. common stock, valued at approximately $70,380, under a pre-existing 10b5-1 trading plan. The shares were acquired upon vesting of restricted stock units on June 11-12, 2026. This is a routine, small-dollar sale consistent with prior plan transactions and does not signal a change in insider sentiment.

Key Facts

  • Insider Berndt Modig (Director and Officer) intends to sell 2,291 shares of PHVS common stock.
  • Estimated aggregate market value of the proposed sale is $70,379.52.
  • Shares were acquired upon vesting of restricted stock units on June 11-12, 2026.
  • The sale is part of a 10b5-1 trading plan, with prior sales under the same plan in April and May 2026.
  • Sale is planned for June 15, 2026 (same day as filing).

Financial Impact

Proposed sale of 2,291 shares worth approximately $70,380, representing a negligible fraction of the $2.1B market cap.

dilution

Risk Factors

  • None material from this filing; the sale is small and pre-planned.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006130
Document: 0001950047-26-006130-index.html0001950047-26-006130
Document: 0001950047-26-006130.txt0001950047-26-006130
37 reports for PHVS
Performance horizon
90% Hit rate 9 of 10 directional calls best @ T+60▲ +21.31%Mar 20, 2026
Filters
Rows
Reports for PHVS — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$38.06 $36.37▲ +4.44%▲ +5.26%$31.07 (+18.38%)
Sep 14, 2026
17d ago
144
NEUTRAL ★ 2/10
$38.06 $35.20▼ −7.51%▼ −9.63%$31.07 (−18.38%)
Sep 14, 2026
18d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.86 $36.02▼ −7.31%▼ −7.41%$31.07 (−20.06%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.02 $36.37▼ −4.34%▼ −4.12%$31.07 (−18.29%)
Sep 8, 2026
24d ago
6-K
BULLISH ★ 8/10
$37.84 $38.86▲ +2.70%▲ +3.36%$31.07 (−17.90%)
Aug 12, 2026
7w ago
6-K
NEUTRAL ★ 6/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 12, 2026
7w ago
Press Release
BULLISH ★ 7/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 6, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$34.45 $34.04▼ −1.19%▼ −2.40%$31.07 (−9.83%)
Jul 6, 2026
12w ago
Press Release
BULLISH ★ 6/10
$33.22 $35.07▲ +5.57%▲ +5.08%$31.07 (−6.49%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$33.86 $35.96▲ +6.20%▲ +5.27%$31.07 (−8.25%)
Showing 10 of 37

US Market Status

Market Open — Closes in 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access